Management of chronic HBV‐HDV patients chronic HBV‐HDV infection: A review on new management options

Buti, María; Gonzalez, Alexia; Riveiro‐Barciela, Mar; Bourliere, Marc

doi:10.1002/ueg2.12494

Cited by 3 publications

(2 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…The results were also best in the groups of patients treated with lonafarnib in combination with pegylated interferon alpha 2a. [21] Nucleic acid polymers and pegylated lambda interferon are other possible future options [21] No response-guided study on the treatment of HDV/HBV infection with pegylated interferon alpha 2a has been published to date. Our study has the advantage of a complete follow-up of the patients for four years and two years of monitoring after the end of the treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D

Gherlan,

Lazar,

Culinescu

et al. 2024

TropicalMed

View full text Add to dashboard Cite

Pegylated interferon alpha 2a continues to be used for the treatment of chronic hepatitis D. The reported on-treatment virologic response varies between 17 and 47%, with relapses in more than 50% of these patients. No stopping rules have been defined, and the duration of the treatment is not clearly established, but it should be between 48 and 96 weeks. In total, 76 patients with compensated liver disease treated with peg-interferon according to the Romanian National protocol for the treatment of hepatitis D were retrospectively included. The duration of treatment was up to 96 weeks, with the following stopping rules: less than a 2 log HDV RNA decrease by week 24 and less than a 1 log decrease every 6 months afterwards. Six months after stopping the treatment, it can be restarted for unlimited cycles. The inclusion criteria were aged above 18, HBs Ag-positive, HDV RNA detectable, ALT above ULN and/or liver fibrosis at least F1 at liver biopsy, or Fibrotest and/or Fibroscan higher than 7 KPa and/or inflammation at least A1 at liver biopsy or Fibrotest. We monitored our patients for a total period of 4 years (including those that repeated the cycle). After the first 6 months of treatment, 27 patients (35.5%) had a greater than 2 log HDV RNA decrease, 19 of them achieving undetectable HDV RNA. Seventeen patients (22.3%) had undetectable HDV RNA 24 weeks after stopping 96 weeks of treatment, and none relapsed in the following 2 years. Of these 17 patients, 6 were cirrhotic, and 4 had F3. Undetectable HDV RNA at 24 weeks was the only parameter that predicted a long-term suppression of HDV RNA. In 49 patients, the treatment was stopped after 6 months according to protocol, but it was restarted 6 months later. Five of these patients finished a 48-week course of treatment; none achieved undetectable HDV RNA. During the first course of therapy, 45 patients had at least one moderate adverse reaction to treatment. In one patient, the treatment was stopped due to a serious adverse event (osteomyelitis). Treatment doses had to be reduced in 29 patients. The virologic response at week 24 can select the patients who will benefit from continuing the treatment from those who should be changed to another type of medication when available.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D

Gherlan,

Lazar,

Culinescu

et al. 2024

TropicalMed

View full text Add to dashboard Cite

show abstract

The HBV/HDV screening and linkage to care in drug users: A therapeutic diagnostic pathway (PDTA)

Nava,

Kondili

2024

Mission

View full text Add to dashboard Cite

The infectious diseases are an important comorbidity in drugs users and a health warming.Today only a few percentages of drug users are subjected to screening for hepatitis and human immunodeficiency virus (HIV).In the recent years an effort has been made in drug users for the elimination of hepatitis C virus (HCV).Unfortunately, several barriers are now limiting the achievement of the goal of HCV elimination, as suggested by WHO.Drug users are people highly at risk to contract HBV and HDV infections. Only a few percentages of drug users receive HBV/HDV treatments, although they are effective and safe. The lack of treatment for drug users may be due to several factors. The main is that only a few percentages of drug users are tested for HBV and linked to treatment.The principal aim of this work is to defi ne a therapeutic diagnostic pathway (Percorso Diagnostico Terapeutico Assistenziale – PDTA) able to favorite HBV/HDV screening and linkage to care in drug users.

show abstract

Coincidence of liver cirrhosis and Cushing's disease

Krausová,

Kosák,

Hříbek

et al. 2024

Vnitr Lek

View full text Add to dashboard Cite

show abstract

Management of chronic HBV‐HDV patients chronic HBV‐HDV infection: A review on new management options

Cited by 3 publications

References 72 publications

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D

The HBV/HDV screening and linkage to care in drug users: A therapeutic diagnostic pathway (PDTA)

Coincidence of liver cirrhosis and Cushing's disease

Contact Info

Product

Resources

About